Microvessel density as a prognostic marker in bladder carcinoma: Correlation with tumor grade, stage and prognosis

Canoğlu, Ali; Göğüş, Çağatay; Bedük, Yaşar; Orhan, Dıclehan; Tulunay, Özden; Baltacı, Sümer

doi:10.1007/s11255-004-8869-9

Cited by 53 publications

(33 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Moreover, angiogenic activity was correlated with a higher incidence of lymph node metastasis and poor prognosis for patients with transitional cell carcinoma of the bladder [22,23] . Mutational studies of the H-ras gene family have demonstrated that an alteration in codons 12 and 61 of the H-ras gene occurs in about 20% of bladder cancers [24] .…”

Section: Discussionmentioning

confidence: 97%

Vascular endothelial growth factor, p53, and the H-ras oncogene in Egyptian patients with bladder cancer

El-Chennawi

Auf²,

Metwally³

et al. 2009

WJGO

View full text Add to dashboard Cite

AIM:To evaluate the relationship between vascular endothelial growth factor (VEGF), p53 , and the H-ras oncogene and different clinicopathological parameters in Egyptian patients with Schistosoma-associated transitional cell carcinoma of the bladder. METHODS:The study included 50 patients with transitional cell carcinoma for whom radical cystectomy and urinary diversions were carried out. VEGF and p53 protein expressions were evaluated with an immunohistochemical staining method, and H-ras oncogene mutations were analyzed with a polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) technique. RESULTS:High grade tumors revealed higher p53 immunostaining than low grade tumors (P = 0.016).p53 and VEGF protein expressions, as well as H-ras oncogene mutations, had an insignificant impact on patient outcomes (P = 0.962, P = 0.791, and P = 967, respectively). Cancer extension to regional lymph nodes was associated with poor outcomes (P = 0.008). CONCLUSION:

show abstract

Section: Discussionmentioning

confidence: 97%

Vascular endothelial growth factor, p53, and the H-ras oncogene in Egyptian patients with bladder cancer

El-Chennawi

Auf²,

Metwally³

et al. 2009

WJGO

View full text Add to dashboard Cite

show abstract

“…There is a long-standing controversy about whether a tumour's MVD can be used to indicate its grade [20][21][22]. Our data in the present study showed no significant difference in MVD values between well to moderately [23] found that the perfusion of well-differentiated HCC was distinct from those of moderately and poorly differentiated HCC, the difference may be due to the different patient population in their study including patients with unresectable or metastatic HCCs, and the timing of their dynamic CT was less than 30 s, in which their perfusion value came from the hepatic arterial perfusion and did not include hepatic portal perfusion; additionally, they categorised patients differently from those in our group.…”

Section: Discussionmentioning

confidence: 99%

Perfusion computed tomography evaluation of angiogenesis in liver cancer

Yang

et al. 2010

Eur Radiol

View full text Add to dashboard Cite

show abstract

“…Given that microvessel density, a surrogate marker for angiogenesis, correlates with progression and poor prognosis in invasive carcinomas of the bladder [10,11], the use of antiangiogenic therapies has started to be considered for bladder cancer patients [12]. This rationale has been also impelled by the recent and rapid development of therapies that selectively inhibit angiogenesis.…”

Section: Effects Of Bevacizumab On Autocrine Vegf Stimulation In Bladmentioning

confidence: 99%

Effects of Bevacizumab on Autocrine VEGF Stimulation in Bladder Cancer Cell Lines

Videira

Piteira²,

Cabral³

et al. 2011

Urol Int

View full text Add to dashboard Cite

Introduction: A functional vascular endothelial growth factor A (VEGF-A) autocrine loop is crucial for bladder cancer cell survival. We reasoned that treatment with the anti-VEGF antibody bevacizumab may result either in cell growth prevention or in the cell adaptation to compensate VEGF deprivation. Methods: The cytotoxicity of different levels of bevacizumab and its effect on the gene expression was analyzed in human bladder cancer cell lines. Results: Inhibition of bladder cancer cell proliferation was observed at >2.5 mg/ml of bevacizumab. Non-muscle-invasive bladder cancer cells expressed high concentrations of VEGF-A, and were less susceptible to bevacizumab inhibition. At 0.5 mg/ml (FDA approved concentration) of bevacizumab, cells increase their expression of VEGF-A, VEGF-A receptors and related growth factors. Conclusions: Bevacizumab cytotoxicity is only observed at high concentration, and it is inversely correlated with the basal VEGF-A expression of the bladder cancer cells. This is the first report showing that, at clinical bevacizumab concentrations, cancer cells compensate the VEGF-A blockade, by improving the expression of VEGF-A and related genes, highlighting the need to follow the patient’s adaptation response to bevacizumab treatment.

show abstract

Microvessel density as a prognostic marker in bladder carcinoma: Correlation with tumor grade, stage and prognosis

Abstract: These data demonstrate that MVD in bladder carcinoma correlates with grade, stage and malignant potential of the tumor. Quantification of tumor angiogenesis may allow selection of the type of treatment for bladder cancer patients.

Cited by 53 publications

References 20 publications

Vascular endothelial growth factor, p53, and the H-ras oncogene in Egyptian patients with bladder cancer

Vascular endothelial growth factor, p53, and the H-ras oncogene in Egyptian patients with bladder cancer

Perfusion computed tomography evaluation of angiogenesis in liver cancer

Effects of Bevacizumab on Autocrine VEGF Stimulation in Bladder Cancer Cell Lines

Contact Info

Product

Resources

About